Cellmid Limited (ASX:CDY) rose 2.4% on Thursday . The stock traded as high as A$0.23 ($0.16) and last traded at A$0.22 ($0.15), approximately 91,419 shares traded hands during mid-day trading. The stock had previously closed at A$0.21 ($0.15).
The company has a debt-to-equity ratio of 21.97, a current ratio of 2.49 and a quick ratio of 1.85. The firm has a market cap of $20.24 million and a price-to-earnings ratio of -2.95. The firm has a fifty day simple moving average of A$0.22 and a two-hundred day simple moving average of A$0.21.
About Cellmid (ASX:CDY)
Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool.
Recommended Story: What is the LIBOR?
Receive News & Ratings for Cellmid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellmid and related companies with MarketBeat.com's FREE daily email newsletter.